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Abstract
Background: Neurofibromatosis 1 (NF1) is a monogenic model for syndromic autism. Statins rescue the social and
cognitive phenotype in animal knockout models, but translational trials with subjects > 8 years using cognition/
behaviour outcomes have shown mixed results. This trial breaks new ground by studying statin effects for the first
time in younger children with NF1 and co-morbid autism and by using multiparametric imaging outcomes.
Methods: A single-site triple-blind RCT of simvastatin vs. placebo was done. Assessment (baseline and 12-week
endpoint) included peripheral MAPK assay, awake magnetic resonance imaging spectroscopy (MRS; GABA and
glutamate+glutamine (Glx)), arterial spin labelling (ASL), apparent diffusion coefficient (ADC), resting state functional
MRI, and autism behavioural outcomes (Aberrant Behaviour Checklist and Clinical Global Impression).
Results: Thirty subjects had a mean age of 8.1 years (SD 1.8). Simvastatin was well tolerated. The amount of
imaging data varied by test. Simvastatin treatment was associated with (i) increased frontal white matter MRS GABA
(t(12) = − 2.12, p = .055), GABA/Glx ratio (t(12) = − 2.78, p = .016), and reduced grey nuclei Glx (ANCOVA p < 0.05,
Mann-Whitney p < 0.01); (ii) increased ASL perfusion in ventral diencephalon (Mann-Whitney p < 0.01); and (iii)
decreased ADC in cingulate gyrus (Mann-Whitney p < 0.01). Machine-learning classification of imaging outcomes
achieved 79% (p < .05) accuracy differentiating groups at endpoint against chance level (64%, p = 0.25) at
baseline. Three of 12 (25%) simvastatin cases compared to none in placebo met ‘clinical responder’ criteria for
behavioural outcome.
Conclusions: We show feasibility of peripheral MAPK assay and autism symptom measurement, but the study
was not powered to test effectiveness. Multiparametric imaging suggests possible simvastatin effects in brain
areas previously associated with NF1 pathophysiology and the social brain network.
Trial registration: EU Clinical Trial Register (EudraCT) 2012-005742-38 (www.clinicaltrialsregister.eu)
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Background
Neurofibromatosis 1 (NF1) is the most common auto-
somal dominant single-gene neurodevelopmental disorder
with incidence of 1:2700, [1] caused by loss of function
mutations in the NF1 gene on chromosome 17q11.2 en-
coding for neurofibromin. Although identified by neuro-
cutaneous manifestations, morbidity in childhood NF1
usually relates to cognitive, social and behavioural difficul-
ties, with moderate cognitive impairment and academic
underachievement in about 80% [2] and attention-deficit/
hyperactivity disorder (ADHD) in 38–50% [2, 3]. Recent
evidence of autism spectrum disorder (ASD) prevalence of
~ 25% with partial traits in a further 20% [4, 5] support
NF1 as a promising single-gene syndromic model for un-
derstanding ASD pathology [6].
The neurobiology of the social and learning deficits in
NF1 has been studied in Nf1+/− mouse models and re-
cent in-human studies [7]. Neurofibromin is a negative
regulator of rat-sarcoma viral oncogene homologue
(Ras); loss of neurofibromin causes disinhibition of the
RasMAPK pathway with consequent GABA/glutamate
disequilibrium, impairment in long-term potentiation
(LTP) and synaptic plasticity [8]. Upregulation of the Ras
pathway can also directly affect myelin formation and
axonal integrity [9] and dysregulate nitric oxide signal-
ling pathways in oligodendrocytes [10]. Recent diffusion
tensor imaging (DTI) study in human NF1 [11] demon-
strated increased apparent diffusion coefficient (ADC)
values localised in the caudate and other deep grey nu-
clei, diencephalon and frontal white matter in NF1 chil-
dren compared to controls, consistent with decreased
neuronal density or myelin sheath disorganisation; the
extent of these effects was associated with neurological
symptoms. Other imaging studies in human NF1 have
identified reduced cortical GABA [12, 13], reduced cere-
bral perfusion [14], alteration in diffusion-weighted im-
aging [15] and abnormal network connectivity on resting
state fMRI [16, 17].
This emerging understanding of NF1 neural system
pathophysiology from animal and human studies has
provided a rationale for experimental intervention trials.
Compensatory downregulation of Ras activation can be
achieved by blocking its farnesylisation, using 3-
hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) re-
ductase inhibitors (statins). Attenuation of Ras activity
in Nf1+/− mouse models using lovastatin [18] or, alterna-
tively, through genetic co-deletion of the Pak1 gene (Nf1
+/−, Pak1+/−) [7] rescues the biochemical, electrophysio-
logical and behavioural deficits, including normalisation
of social memory and autism-like behavioural pheno-
types. Convergence in effect of these two methods sup-
ports the specificity of the target mechanism. Further,
the Pak1 gene co-deletion experiment illustrated the po-
tential of such studies to illuminate causal pathogenic
pathways, by suggesting functional localisation of the
primary Ras-related pathology in the amygdala and other
parts of the social brain network, and causal involve-
ment of specific synaptic proteins [7].
Translational statin intervention studies in human
NF1, based on the Ras downregulation hypothesis, have
had mixed results. Improvements in verbal and non-
verbal memory were reported within a 12-week phase 1
single-arm study examining the safety and tolerability of
lovastatin in 23 children aged 10–17 years [19] and in a
14-week randomised controlled trial (RCT) of lovastatin
in 44 10–50-year-olds [20]. Normalisation of pseudo-
resting state functional connectivity in areas of the
default mode network (DMN) following lovastatin treat-
ment was found in a case series of 7 children from the
prior child cohort [21]. A case-control study of trans-
cranial magnetic stimulation in 11 adults with NF1
showed impaired synaptic plasticity and deficits in
phasic alertness at baseline compared to controls, which
improved after 4 days of high-dose (200 mg) lovastatin
[22]. However, larger statin trials have found little effect.
A 12-week double-blind, placebo-controlled RCT of
simvastatin in 62 children with NF1 aged 8–16 found no
group differences on primary behavioural outcome mea-
sures and minimal improvements in cognitive aspects of
visual synthesis in the simvastatin group; [23] another
RCT of simvastatin (84 children aged 8–16 years) found
no improvements in cognitive deficits or parent-
reported behavioural problems [24]. A 16-week RCT of
lovastatin in 146 8–15-year-olds with NF1 and visuo-
spatial learning/attention deficits found no improve-
ments on a paired associate learning task [25].
This human intervention work has been on mid-
childhood or older cohorts rather than in earlier
development. Trials have also not specifically targeted
NF1-autism behavioural outcomes or used multipara-
metric imaging techniques. We report here therefore on
the first experimental trial of a statin in young children
with NF1 with co-occurring autism, using detailed
multilevel measurements designed to assess the patho-
genic pathway identified in NF1 animal models from
gene disruption to cognitive and behavioural pathology.
These included (i) statin effects at a cellular level on Ras
activation, using peripheral MAPKinase assay; (ii) multi-
parametric imaging to reflect different related aspects of
neural system structure, neurophysiology and in vivo
function; and (iii) NF1-relevant cognitive and autism-
related behavioural outcomes. By investigating statin ef-
fects on these different levels, we aim to illuminate the
dynamics and possible causal relationships of this patho-
genic pathway in humans. Hypotheses were that (i) sta-
tin treatment in young children with NF1-autism would
be feasible, safe and acceptable to families; (ii) peripheral
MAPKinase assay and awake multiparametric imaging
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could be acquired; and (iii) that although the study was
not powered for definitive treatment effect estimation, sig-
nals of change in MAPK and multimodal imaging parame-
ters would be detectable, along with change in autism and
other cognitive and behavioural symptoms. Specific im-
aging parameters for testing and hypothesised parameter
changes were selected on the basis of the existing imaging
literature in NF1, especially those linked to known abnor-
malities in idiopathic autism. Thus, we expected normal-
isation of the reduced GABA and perfusion metrics, and
reduction in the abnormalities in DTI and connectivity
metrics found in NF1 (see “Methods” section).
Methods
Design and participants
A single-site triple-blind (clinician, family, assesor) RCT
of simvastatin vs. placebo in children with NF1-autism,
the SimvAstatin in Neurofibromatosis Type 1-Autism
(SANTA) trial, was registered with EudraCT number
2012-005742-38. Study protocol is available on http://
research.bmh.manchester.ac.uk/santa. Participants were
children between 4.5–10.5 years meeting diagnostic cri-
teria for (i) NF1 (National Institutes of Health criteria)
[26] (ii) autism spectrum disorder (ASD) using
Collaborative Program of Excellence in Autism (CPEA)
criteria, based on Autism Diagnostic Interview-Revised
(ADI-R), Autism Diagnostic Observation Scale-2 and
WASI (Wechsler Abbreviated Scale of Intelligence) ver-
bal IQ, [27] after positive initial screening (T > 60) on
parent-rated Social Responsiveness Scale (SRS). They
were recruited via local and regional UK NF1 clinics
(Manchester, Leeds, Newcastle, Edinburgh, Wirral,
Warrington and Edinburgh, UK) and through NF char-
ities’ newsletters, websites and social media pages. Exclu-
sion criteria were (i) severe learning disability (WASI
verbal IQ < 50); (ii) in active treatment for another NF1
complication (e.g., chemotherapy for optic pathway or
other low-grade glioma, Ilizarov frame for pseudarthro-
sis) or clinically significant unrelated illness; (iii) abnor-
mal liver function or creatinine kinase at baseline (iv)
parents of participants with insufficient English to
complete the ASD screening assessments; (v) use of psy-
chotropic medication other than stimulants, current
simvastatin use or any investigational drug within
4 months of screening; (vi) participants with planned
surgery within 16 weeks of potential enrolment. Partici-
pants on a stable dose of stimulants for at least 3 months
prior to screening were permitted to participate.
Measures
MAPK assay (baseline, 12-week endpoint) in peripheral
lymphocytes was used as a marker of the effectiveness of
statin-induced downregulation of the intracellular Ras
pathway. In animal models, peripheral estimation of this
kind has shown consistency with neural Ras activity, and
in humans, has been associated with cognitive function in
Alzheimer’s disease and cognitive impairment [28, 29].
Details of methodology and assay are given in
Additional file 1.
Brain imaging (baseline, 12-week endpoint) on a
Philips 3T Achieva scanner (Eindhoven, The
Netherlands) was implemented using a 32-channel head
coil for signal reception and body coil for transmission
with no contrast or sedation. Imaging parameters were
purposefully selected on the basis of prior hypotheses re-
lating to existing imaging findings in NF1 on cortical
GABA spectroscopy [12, 13], MR cerebral perfusion
[14], alteration in diffusion-weighted imaging [15] and
abnormal network connectivity on resting state fMRI
[16, 17]. Additional file 1: Table S1 outlines the imaging
protocol, along with our patient preparation protocol to
facilitate awake scanning in this challenging imaging co-
hort. No visual stimulation was allowed for the initial
resting state fMRI acquisition, but following this, the
children were allowed to watch a projected film of their
choice or listen to music if they preferred. Imaging data
were acquired at week 0 and then again following either
exposure to placebo or simvastatin for 12 weeks. In four
cases, where the initial imaging dataset was incomplete,
a week 4 scan was performed which acquired only the
missing week 0 imaging datasets (T1 volume and
diffusion data).
Autism symptoms (baseline, 4 weeks, 12-week end-
point) were quantified using standard measures of
proven specificity and sensitivity to treatment effect over
short periods and widely used in autism psychopharma-
cology trials [30, 31]. Parent-rated Aberrant Behaviour
Checklist (ABC) [32] has 58-items on 1–4 Likert scale
with five subscales: irritability, hyperactivity, lethargy/
withdrawal, stereotypy and inappropriate speech. Parent-
defined target symptoms [33] was based on blinded re-
searcher interview. One or two problems of greatest
concern to parents at baseline, rated on frequency, dur-
ation, intensity and functional impairment, were
assessed on a 9-point scale as 1 = normal, 2 =markedly
improved, 3 = definitely improved, 4 = equivocally better,
5 = no change, 6 = equivocally worse, 7 = definitely
worse, 8 =markedly worse, and 9 = disastrously worse.
Ratings across the two target symptoms were averaged.
Clinical Global Impression Scale (CGI-S) [34] was used
in measuring severity of psychopathology on a 7-point
scale, change from the initiation of treatment on a simi-
lar 7-point scale and the drug efficacy index. Over three
decades of research the CGI correlates well with stand-
ard research drug efficacy scales [34]. Overactivity symp-
toms were assessed using the standard parent-rated
Conners questionnaire [35]. Following standard practice
in autism medication trials [36], clinical responders were
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defined as children with 25% reduction in the parent-
rated ABC irritability score plus a rating of ‘much im-
proved’ or ‘very much improved’ on the clinician-rated
CGI scale.
Acceptability
Telephone interviews were conducted at 16 weeks
(4 weeks after the end of the trial) by researchers inde-
pendent of the trial research team, and blind to treat-
ment arm, to assess parent acceptability of the trial
protocol. This 19-item interview was rated on a 5-point
Likert scale from strongly disagree to strongly agree for
each stem statement.
Procedures
Eligible participants were randomised on a 1:1 ratio by the
clinical trial pharmacy at Manchester Univer-
sity NHS Foundation Trust using web-based randomisa-
tion with blocks of 2 and 4. The results of the
randomisation were not communicated outside the phar-
macy, which delivered the appropriate masked drug bot-
tles to the research team. All investigators, participants
and their parents were kept masked to treatment
allocation.
Simvastatin is an HMG-CoA reductase inhibitor. It has
a UK and US licence for use in age 10 and above, and
there is extensive off-label clinical experience of its use in
younger children with other disorders such as familial
hypercholesterolaemia and Smith Lemli Opitz Syndrome.
The bioavailability of simvastatin is 42.5% ± 42.5. The only
other available statin which crosses the blood brain barrier
(lovastatin) is not licenced for use in children in Europe.
Assessments were carried out at the NIHR/Wellcome
Trust Clinical Research Facility, Manchester University
NHS Foundation Trust at baseline and weeks 4 and 12.
After baseline and randomisation, participants were
treated with simvastatin or placebo in liquid preparation
at 0.5 mg/kg in a single daily dose. At week 4, in the ab-
sence of any reported adverse effects, or abnormalities of
plasma biochemistry (LFTs and CK), simvastatin dose was
increased to 1 mg/kg/day to a maximum of 30 mg/day.
This dosing regime was similar to those used in other
studies of simvastatin in young children [37] and was se-
lected for known safety and indirectly for known efficacy
in such other contexts.
Consent and ethics
We obtained informed oral and written consent from
parents and assent from children where developmentally
appropriate. The local ethics committee approved the
study (REC Reference 13/NW/0111). The trial was con-
ducted in agreement with the Declaration of Helsinki
and Good Clinical Practice Guidelines.
Statistical analysis
Behavioural measures
Statistical analysis was performed in Stata version 14,
based on an intention-to-treat approach using all rando-
mised patients and followed the CONSORT statement
and trial protocol. The only protocol measure not
presented in this report is the Judgement of Line
Orientation Test, for which insufficient analysable data
were available (details in Additional file 1). The primary
analysis was based on tabulated and associated graphical
summaries of feasibility indicators: patient recruitment,
checks for the absence of selective recruitment of partic-
ipants; baseline balance of summary statistics and pa-
tient flow. The study was not powered for formal
analysis of between-group treatment effect on clinical
and behavioural outcomes; the presented results focus
on point estimates and associated 95% confidence inter-
vals rather than statistical significance. Analysis was per-
formed using linear regression models to estimate the
effect of random allocation on autism and behavioural
symptom outcomes at 12 weeks, adjusting for baseline
values of the relevant outcome as a linear covariate.
Bootstrapping with 500 replications was used to estimate
standard errors for all models.
Imaging analysis (further details in Additional file 1)
GABA spectroscopy GABA measurements were taken
from (i) frontal white matter (FWM) and (ii) deep grey
nuclei (DGN) using the localised spectroscopy sequence
MEGA-PRESS, using the unsuppressed water signal as a
reference. GABA measurement is defined as ‘GABA+’,
due to macromolecular signal contribution [38]. The
sum of glutamate and glutamine (Glx) was measured via
the same acquisition, giving a peak centred at 3.75 ppm.
A non-water-suppressed acquisition from the same loca-
tions was acquired to act as reference. Statistical analyses
in SPSS 22.0 considered the absolute and between-group
change from baseline to endpoint, with and without ad-
justment for baseline variation. Parametric (t test) and
non-parametric (Mann-Whitney test with covariate ad-
justment) [39] tests were used for comparison, based on
normality of the data. No correction was made for test-
ing across multiple regions.
Perfusion imaging Pulsed arterial spin labelling images
were acquired using a modified ‘STAR’ technique [40],
together with co-aligned proton density images. Perfu-
sion images were obtained by subtracting control images
from labelled images and fitting to a single blood-
compartment model using an in-house code provided by
LP (see Additional file 1: Table S1). The median regional
CBF values were calculated following CBF map registra-
tion to the corresponding structural T1 images.
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Diffusion imaging We applied a diffusion-weighted
multislice spin echo single-shot echo planar imaging se-
quence transaxially: slices 55 contiguous, b = 1000 s/
mm2 (Δ/δ 36.4/22.7 ms) in 6 non-collinear directions.
One volume (b0 image) was also acquired without a dif-
fusion gradient; b = 0 s/mm2. The median regional ADC
values were calculated following ADC map registration
to the corresponding structural T1 images.
Resting state fMRI Single-shot, whole brain coverage,
echo planar imaging was used to acquire resting state
data (Additional file 1: Table S1). Spatial networks dem-
onstrating strong temporal co-activation in the resting
BOLD fMRI responses were defined using probabilistic
independent component analysis (ICA). The analysis for
differences between groups was performed using a dual
regression technique, which allowed for voxel-by-voxel
comparisons of functional connectivity.
Machine learning The whole imaging dataset was ana-
lysed for stratification into simvastatin or placebo groups
with a Random Forest machine learning classifier.
Cross-validation was performed, such that each fold
contained at least one example of each group. The sig-
nificance of the resulting area under the curve (AUC)
score was assessed using a test where the group labels
were permuted (Python scikit-learn library) [41].
Results
Trial flow
Additional file 1: Figure S4 shows the CONSORT flow
chart for the study. Ninety-one completed parent-
reported SRS questionnaires were received between
October 2013 and June 2015. Of these, 71 met eligibility
criteria and were invited for in-depth assessment; 53
were seen for baseline ASD assessments, from which 30
met CPEA criteria for ASD and were randomised (pla-
cebo, 16; simvastatin, 14); 26 completed endpoint assess-
ment at 12 weeks. All analyses were by assigned groups.
Demographics and baseline status
Additional file 1: Tables S2 and S3 shows baseline demo-
graphic and clinical data for the two groups. The mean
age of the sample was 8.10 years. Two participants in the
simvastatin arm and two in the placebo arm had a pre-
existing diagnosis of ADHD and were on stimulant medi-
cation. Baseline measures including ADI-R, ADOS, Verbal
IQ and SRS scores were generally well matched across the
groups, and the screening and diagnostic autism measures
all showed values well within the standardised autism
range (Additional file 1: Table S2). In the simvastatin
group, 21.4% had inherited the NF1 mutations as opposed
to 62.5% in the placebo group, but we have no evidence of
any differential effect from familial or sporadic cases on
any baseline or outcome variable from our previous stud-
ies [4, 42]. Genotype data on the cohort is presented in
Additional file 1: Table S7 where it is also compared to a
large recently published genotyped cohort from our group
[43]. There are no obvious differences in mutation type
between the SANTA cohort and the larger cohort, sug-
gesting representativeness of the SANTA cohort. There
was no SPRED1 and only one microdeletion in the cohort.
Patient defined target symptoms included hyperactivity,
aggression, social inappropriateness, difficulties with com-
munication, inflexibility/obsessionality and learning prob-
lems. In four cases (three in simvastatin, one in placebo),
there was movement artefact on the T1 volume and
diffusion sequences, and these parameters were then re-
acquired at week 4 visit.
Acceptability
Sixteen-week telephone interview data was available for
25 participants. The scanning protocol was acceptable
for all of these families, 21/25 families felt that the ha-
bituation CD helped with the scanning process.
Adverse events
Adverse events (AEs) recorded are set out in
Additional file 1: Table S4. These were all minor and not
specific to the simvastatin arm; none resulted in drug
discontinuation or dose reduction. There were no severe
adverse events or suspected unexpected serious adverse
reactions.
Outcome estimation
Peripheral MAPK activity
Completed assay was achieved in 27/30 cases (12/14
simvastatin, 15/16 placebo) at baseline and 22/26 (9/11
simvastatin, 13/15 placebo) at endpoint. Missing data is
related to inadequate venesection volumes and the need
to prioritise adverse event monitoring. Representative
Western blot assays are shown in Fig. 1 and quantifica-
tion of outcomes in Additional file 1: Figure S6. Assay
results showed wide variance; robust estimation using a
linear method gave a moderate between-group treatment
effect size point estimate of 0.60 reduction of pMAPK in
favour of intervention, but with 95% CI − .34 to 1.54,
ranging from small increase to large reduction (Fig. 2).
Imaging
MR spectroscopy MRS data was acquired for frontal
white matter (FWM) in 27/30 cases at baseline and 19/26
at endpoint. Within this, endpoint voxel assessment of
GABA+ data was possible in 5/11 simvastatin and 9/15 pla-
cebo and showed a trend towards between-group increase
in the simvastatin group compared to placebo (mean 1.82
placebo vs. 2.39 simvastatin (t(12) = − 2.12, p = .055, two-
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tailed uncorrected), although this was not present when
adjusted for baseline values (ANCOVA p = 0.188, Mann-
Whitney p = 0.66; Fig. 3a). Glx showed no effect, but
GABA/Glx ratio showed significant endpoint difference
(t(12) = − 2.78, p = .016 two-tailed, uncorrected). MRS data
for deep grey nuclei (DGN) was acquired in 24/30 at base-
line and 23/26 at endpoint. Pre-post analysis was possible
on 13 simvastatin and 12 placebo; it showed no change in
GABA+ value but a significant post-treatment reduction in
Glx compared to placebo (ANCOVA p < 0.05, Mann-
Whitney p < 0.01; Fig. 3b), although uncorrected for a
significantly lower Glx in the treatment group at baseline
(t(18) = − 3.08, p = .006).
Perfusion and diffusivity assessment Validated data
for diffusion analysis were acquired on 20/30 cases at
baseline (10/14 simvastatin, 10/16 placebo) and 16/26
at endpoint (8/11 simvastatin, 8/15 placebo). Perfusion
data analysis was available on 28/30 cases at baseline
(12/14 simvastatin cases and 14/16 placebo) and 23/30
cases post treatment (10/14 simvastatin and 13/16
placebo). Analysis of available paired pre-post data (7
simvastatin and 13 placebo) showed significant increase
in perfusion within the ventral diencephalon associated
with statin treatment (ANCOVA p < 0.01 and Mann-
Whitney p < 0.01, uncorrected; Fig. 4a). Analysis of
available paired pre-post data (5 simvastatin and 6 pla-
cebo) showed decrease in ADC within the cingulate gyrus
associated with statin treatment (ANCOVA p = 0.01,
Mann-Whitney p < 0.01, uncorrected; Fig. 4b).
Resting state fMRI Probabilistic ICA identified the
default mode network (DMN) separately in both base-
line (10/14 simvastatin, 11/16 placebo) and week 12
(6/11 simvastatin, 11/15 placebo) rsfMRI acquisitions.
Dual regression did not identify any significant differ-
ences between simvastatin and placebo groups in the
DMN spatial maps when tested at the 5% significance
level (corrected for multiple comparisons). However,
at the 10% significance level foci of decreased co-
activation in the simvastatin group compared to pla-
cebo were seen within the right occipital lobe and left
perirolandic region (p = 0.093 and 0.092, respectively,
corrected, voxel counts 11 and 3; Fig. 5). No signifi-
cant differences were seen at the 10% level in the
DMN at week zero nor in the sensorimotor or medial
visual networks at either time point.
Machine learning The whole imaging dataset was en-
tered for analysis. Baseline classification accuracy was
64% (p = 0.25) compatible with stratification into groups
on the basis of chance alone. Following treatment, the
features with best statistical power for group allocation
were the ADC values in the occipital cortex, the occipi-
tal white matter and the parietal white matter. We com-
pared changes in the left- and right-sided ADC metric in
these regions between both groups and found classifica-
tion accuracy rose from baseline to 79% (p < 0.05; Fig. 6),
suggesting a simvastatin treatment effect.
Behavioural outcomes
Behavioural symptom endpoint outcomes are shown in
Table 1 (and week 4 intermediate outcomes in
Additional file 1: Table S5). The trial was not powered to
show significant between-group behaviour effects, and
Fig. 1 Representative Western blot showing p MAPK (top) and total MAPK (bottom) levels in peripheral blood mononuclear cells from NF1
patient treated either with placebo or simvastatin
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Fig. 2 Distribution of MAP Kinase Assay levels at baseline and
endpoint
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none were seen. At endpoint, 3/12 (25%) of the statin
treatment cases were classified as clinical responders
using standard RUPP (Research Units of Paediatric Psy-
chopharmacology) criteria [26] compared to 0/14 (0%)
in the placebo group. Each of these responders also met
subsidiary standards for response on the patient-defined
target symptoms (PDTS < 3). Two further cases in the
statin group and 2/14 in the placebo group met PDTS
responder criteria only. The responder group (n = 3) was
characterised clinically by being male, with the mean age
of 9.29 years (SD 0.77), with a relatively high-baseline
ADOS total score of 17.0 (SD 1.73) but other metrics
similar to group means (baseline SRS total score = 87.6
(SD 2.08), ADI-R social interaction 20.66 (SD 1.52),
communication 15 (SD1.73) and RRBs 5.33 (1.55).
Discussion
Previous statin trials in older children and adults have
shown mixed effects, but most used lovastatin and mea-
sured outcomes at just cognitive or behavioural levels.
This trial used simvastatin, considered the most effective
neuroprotective statin [44]. It is also the first trial that
has looked in detail at statin effects on ‘upstream’
process at cell and neural system levels, reflecting a
pathogenic pathway between gene disruption and the
autism-related behavioural psychopathological outcomes
known in NF1. We interpret the outcomes therefore in
relation to each of these levels, while acknowledging that
the restricted sample size in this data-rich trial, and the
variable amounts of data available for different analyses,
limits precision of estimation.
At the cellular level, the moderate between-group
point estimate showing peripheral lymphocyte reduction
of MAPK function was in the hypothesised direction,
consistent with a statin effect at the cell level on the Ras
pathway activation; the wide 95% CI values ranged from
a large decrease to a small increase. Preparation, inter-
national transport and storage of the samples may have
introduced increased variance in the assay results.
At a neural system level, neuroimaging shows evidence
of specific statin effects in regions of interest of the brain
including frontal white matter, deep grey nuclei (lenti-
form, caudate and thalamic nuclei), cingulate gyrus, ven-
tral diencephalon and occipital/occipito-parietal cortex.
Detection of GABA in white matter has been reported
in other studies, albeit at lower levels than in grey matter
[45]. The effects of the statin on the multiparametric
data are in a direction consistent with normalising many
aspects of the underlying NF1-related neuropathology
identified in previous studies. Thus, the suggested in-
creased absolute GABA levels in frontal white matter is
consistent with reversing the reduced cortical GABA
found in previous studies in children and young adults
with NF1 [12, 13] (a contrast to the increase found in
animal experiments [7, 18]). The variation in GABA
findings by brain region in our study is echoed in a
Fig. 3 MR spectroscopy; change in a frontal white matter (FWM) GABA and b deep grey nuclei (DGN) Glx
Fig. 4 a Change in perfusion measured from ASL in the ventral diencephalon and b changes in ADC value in the cingulate cortex
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Table 1 Endpoint behavioural outcomes
Week 12 outcomes Summary statistics Mean difference
Sample Placebo Simvastatin Adjusted mean difference (95% CI) Bootstrap SE Effect size (95% CI) Number analysed
ABC N = 28 N = 15 N = 13
Irritability 19.14 (11.62) 16.40 (10.82) 22.31 (12.14) 1.66 (− 4.61, 7.93) 3.20 0.14 (− 0.40, 0.68) 28
Lethargy* 12.63 (10.01) 10.53 (9.61) 15.25 (10.30)* 3.60 (− 4.09, 11.28) 3.92 0.29 (− 0.41, 1.13) 26
Stereotypy 5.71 (5.08) 3.93 (3.63) 7.77 (5.83) 1.61 (− 0.98, 4.20) 1.32 0.32 (− 0.19, 0.83) 28
Hyperactivity 23.61 (13.68) 19.13 (13.17) 28.77(12.83) 3.87 (− 3.28, 11.01) 3.65 0.28 (− 0.24, 0.80) 28
Inappropriate speech 5.89 (3.11) 4.80 (2.54) 7.15 (3.31) 1.77 (− 0.10, 3.63) 0.95 0.57 (− 0.03, 1.17) 28
25% reduction
irritability subscale
N = 11 N = 5 N = 6
Conners N = 28 N = 15 N = 13
Inattention 77.25 (12.57) 74.53 (14.16) 80.38 (10.08) 5.33 (− 0.96, 11.61) 3.21 0.42 (− 0.08, 0.92) 27
Hyperactivity 73.54 (15.92) 69.40 (17.12) 78.31 (13.51) −0.98 (− 8.09, 6.13) 3.63 −0.06 (− 0.51, 0.39) 27
Learning problems 69.25 (14.62) 65.40 (12.91) 73.69 (15.71) 1.59 (− 2.13, 5.30) 1.89 0.11 (− 0.15, 0.36) 27
Executive function 71.82 (14.59) 68.20 (16.24) 76.00 (11.66) 4.04 (− 2.51, 10.59) 3.34 0.28 (− 0.17, 0.73) 27
Aggression 70.43 (18.98) 68.40 (20.86) 72.77 (17.09) − 0.05 (− 11.05,10.96) 5.61 − 0.00 (− 0.58, 0.58) 27
Peer relations 83.89 (11.53) 82.00 (13.51) 86.08 (8.73) 1.38 (− 4.45, 7.21) 2.97 0.12 (− 0.39, 0.63) 27
Parent-defined target
symptoms (PDTS)
N = 26 N = 14 N = 12
Mean (SD) 3.52 (1.77) 3.75 (1.86) 3.25 (1.68)
Responders
(PDTS score < 3)
7 2 5
CGI* N = 26 N = 14 N = 12
Global improvement
Mean (SD)
3.31 (0.84) 3.57 (0.85) 3.00 (0.74)
Treatment responder+ N = 3 N = 0 N = 3
*1 additional observation missing. +Treatment responder defined as > 25% reduction in ABC irritability subscale and a score of improved or much
improved on CGI
Higher scores on ABC, Conners and CGI are indicative of higher levels of impairment
Fig. 5 rsfMRI a default mode network (DMN) demonstrated by probabilistic group ICA of week 12 acquisitions (axial, coronal, sagittal). b At week
12, foci of decreased DMN co-activation were identified at the 10% level within the right occipital and left perirolandic regions. No significant
differences in the DMN were identified at the 5% level, corrected
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recent NF1 animal study, [46] reporting differential
localization of GABA between prefrontal cortex and
hippocampus and speculating that this may relate to
differential effects on pre- and post-synaptic recep-
tors. In the future, it would be possible to study this
important variability further in humans by measuring
GABA type A receptor binding using [11C]-flumaze-
nil PET alongside GABA concentration with MRS, as
in [12].
Interpretation of our evidence suggesting reduced Glx
concentration in deep grey nuclei in relation to the exist-
ing NF1 literature is uncertain since findings on Glx
concentration in NF1 have been previously conflicting.
However, in young children with idiopathic autism, ele-
vated deep brain Glx has been found in the anterior cin-
gulate cortex in one large sample study [47] and
reported to correlate with quality of social interaction in
another [48]. The finding in this current study therefore
can be interpreted within this context as positive in rela-
tion to autism symptoms.
The reduction in ADC found within the cingulate
gyrus, and the significant ADC finding within the ma-
chine learning analysis, needs to be interpreted in the
context of other work, which has shown increased ADC
and decreased FA values in NF1 including in the cingu-
late [15]. Such findings suggest reduction in cellular
packing and intra-myelinic oedema and have been asso-
ciated with NF1 neurological symptom status [11]. The
effects found in this current study therefore are consist-
ent with reduced extra-cellular water free diffusion in
NF1, and a positive simvastatin effect to reduce intra-
myelinic oedema and improve cellular packing. The
presence of microstructural abnormalities, reflected in
increased ADC values, have also been described beyond
NF1 in idiopathic autism [49–51] and potentially give
these findings wider relevance in relation to this NF1-
autism cohort.
The increased perfusion in the ventral diencephalon
can be understood in the context of diminished perfu-
sion in cingulate gyrus, medial frontal cortex, centrum
semiovale, thalamus and temporo-occipital cortex found
in NF1 children (n = 14, mean age = 10.2 years) [14] and
related hypo-metabolism predominantly within the thal-
amus in FDG PET studies [52–54]. Statins may increase
cerebral blood flow by improving cerebral vasomotor re-
activity through increased NO bioavailability, promotion
of microvascular reperfusion, and enhanced eNOS in the
thalamus, as well as cerebellum, visual cortex and
posterior cingulate [55].
No statistically robust difference in the DMN was
identified between treatment and placebo groups, but
findings at the 10% level raise the possibility of a trend
that might be detected in a larger study. Diminished
functional connectivity has been found in the posterior
cingulate in human NF1 [16], and there is evidence from
a small case series with children that statin treatment
can induce improvements in functional connectivity in
posterior cingulate cortex [21]. Here, simvastatin could
potentially be acting in a focal manner on microstruc-
tural and vascular changes resulting in better regulation
of function through a regional improvement in myelin-
ation and resultant neuronal function.
For behavioural outcomes, while the sample was too
small for definitive estimation, we found that 25% of the
simvastatin sample, compared to none of the placebo
group, showed a clinical response using standard criteria
measured using independently triangulated parent-
report with clinician judgement.
Limitations
Dosing of simvastatin in this study was based on safety
and efficacy evidence from use of statins in other human
disease contexts; we do not know how appropriate it
might be for effectiveness in this context. Animal work
Fig. 6 Three-dimensional plot of the ADC values in the occipital cortex, parietal and occipital white matter; right vs. left
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showed phenotypic rescue [12] with lovastatin at doses
equivalent to those commonly prescribed for children
(AJS, data not shown); however, differences in mode of
delivery (intraperitoneal in animal studies) and the rela-
tive brain penetration of the statins (much higher in
simvastatin) make direct comparison between the animal
and human studies not meaningful. A valuable next step
in this context would be further pre-clinical dose-finding
studies in animal models using both statins with a mode
of administration comparable to that in humans. Our
treatment study was relatively short term, and we cannot
generalise in relation to any longer term effects. There is
no controlled data as yet to confirm a specific link be-
tween peripheral pMAPK assay and neural Ras function
in human NF1 (although links have been found in cogni-
tive impairment and Alzheimer’s disease); further work
will be necessary to confirm its value as a biomarker.
Due to the technical challenges of imaging children with
developmental disability at this age, the amount of ana-
lysable data varied for each imaging parameter. The
study was not powered for a formal test of effectiveness;
inferences on statin effects are preliminary and serve to
indicate hypotheses and outcomes of interest for future
larger scale work.
Conclusions
This study demonstrates the acceptability and safety of
simvastatin treatment for young children with NF1 and
autism; feasibility of awake scanning, data acquisition
and peripheral biomarker assay in such children given
the right preparation; and the value of such a multipara-
metric approach in capturing the likely complexity of
pathogenic mechanisms.
The trial findings are suggestive of specific simvastatin
effects in brain areas that have been shown to be part of
NF1 neural pathology in previous studies. Furthermore,
many of these areas have functional significance as part
of the ‘social brain network’, highly associated with social
impairment and autism psychopathology [56]. This func-
tional localisation may thus be relevant both to the high
autism prevalence in NF1 and to how simvastatin could
have specific remedial effects on NF1-autism at the level
of brain structure and function.
In terms of pathophysiological mechanism, the initial
rationale for statin intervention was its action in NF1
animal models to downregulate the Ras pathway with
consequent effect to reduce GABA, improve synaptic
long-term potentiation and rescue the behavioural
phenotype [7, 8, 18]. This trial in young children gives
evidence consistent with that model operating in
humans through its evidence of a simvastatin treatment
effect (albeit with wide CI) towards reduced cellular
pMAPK activation on peripheral assay, and associated
biologically plausible effects found on GABA/glutamate
balance in FWM and DGN. However, the results also
suggest simvastatin action through additional mecha-
nisms, such as direct effects on myelin formation and re-
gional axonal and astrocyte integrity in NF1. Pleiotropic
effects of this kind from statins in the CNS are well
recognised [57–59]. Our findings further suggest that
treatment may affect such mechanisms in relevant
functional brain areas in NF1 autism. This has future
potential for insights into causal pathogenesis in aut-
ism and NF1 as well as suggesting more focused
treatment targets. Larger studies will be necessary to
further test these possibilities and to link them to any
confirmed effect on behavioural symptom outcomes.
While the initial results are encouraging and suggest
specific hypotheses for further testing, this prelimin-
ary study was not powered to provide evidence to
support clinical use of simvastatin in the disorder in
children at this time.
In a wider context, the SANTA trial is, to our know-
ledge, the first RCT in syndromic autism, or indeed in
clinical neuroscience generally, to have successfully
tested effects simultaneously on relevant cellular activity
markers, neural system multiparametric imaging and be-
havioural outcomes. As such, it provides a model of a
new cohort of experimental intervention designs to link
brain process and behavioural outcomes in the context
of an experimental intervention trial. This has the even-
tual goal of treatment discovery in autism, plus the illu-
mination of pathogenic pathways from gene effect to
behavioural outcome in neuropsychiatric disorder;
in terms of both regional brain localization and under-
lying pathogenic mechanisms.
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